The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
miRNA-202 in bone marrow stromal cells affects the growth and adhesion of multiple myeloma cells by regulating B cell-activating factor
Abstract
Bone marrow stromal cells (BMSCs) up-regulate B cell-activating factor (BAFF) in multiple myeloma. Increasing experimental evidence has shown that microRNAs play a causal role in hematology tumorigenesis. In this study, we characterized the role of miR-202 in regulating the expression of BAFF in BMSCs. It was found that expressions of BAFF mRNA and protein were increased in BMSCs treated with miR-202 inhibitor. The growth rate of miR-202 mimics transfection cells was significantly lower than that of non-transfected cells. The expression of Bcl-2 protein was down-regulated, and Bax protein was up-regulated after miR-202 mimics transfection. Over-expression of miR-202 in BMSCs rendered MM cells more sensitive to bortezomib. More significantly, the regulatory effect of miR-202 could inhibit the activation of NF-κB pathway in BMSCs. These results suggest that miR-202 functions as a modulator that can negatively regulate BAFF by inhibiting MM cell survival, growth, and adhesion in the bone marrow microenvironment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is commonly known that miRNAs interfere with target genes, signaling molecules, and pathways within the context of the BM microenvironment, hence contributing to the pathogenesis of MM [167–169].”
From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [167]
Citations
Cites
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1997 · Cited by 7,723
The Versatile Role of microRNA-30a in Human Cancer
Wang, C., Yang, X., Chen, Y., & Chen, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471111 · Cited by 3,409
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
microRNAs in cancer management
Kong, Y. W., Ferland-McCollough, D., Jackson, T. J., & Bushell, M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70073-6 · Cited by 734
Fisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9665 · Cited by 704
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
Pichiorri, F., Suh, S.-S., Ladetto, M., Kuehl, M., Palumbo, T., Drandi, D., Taccioli, C., Zanesi, N., Alder, H., Hagan, J. P., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806202105 · Cited by 563
Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Rème, T., Lugagne, C., Moine, P., Rossi, J.-F., Klein, B., & Tarte, K. (2004) · Blood · doi:10.1182/blood-2003-06-1984 · Cited by 558
Gupta, D., Treon, S., Shima, Y., Hideshima, T., Podar, K., Tai, Y., Lin, B., Lentzsch, S., Davies, F., Chauhan, D., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402295 · Cited by 553
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Podar, K., & Anderson, K. C. (2005) · Blood · doi:10.1182/blood-2004-07-2909 · Cited by 343
Bone marrow microenvironment and the identification of new targets for myeloma therapy
Podar, K., Chauhan, D., & Anderson, K. C. (2009) · Leukemia · doi:10.1038/leu.2008.259 · Cited by 337
Research works printed but not linked: 1
- Hao M, Zhang L, An G, et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma. 2011;52:1787–94. · DOI
Cited by
Cheng, Q., Li, X., Wang, Y., Dong, M., Zhan, F., & Liu, J. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.118 · Cited by 104
Roles of miRNA dysregulation in the pathogenesis of multiple myeloma
Chen, D., Yang, X., Liu, M., Zhang, Z., & Xing, E. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-00291-4 · Cited by 82
MicroRNAs and exosomes: Small molecules with big actions in multiple myeloma pathogenesis
Pourhanifeh, M. H., Mahjoubin‐Tehran, M., Shafiee, A., Hajighadimi, S., Moradizarmehri, S., Mirzaei, H., & Asemi, Z. (2019) · IUBMB Life · doi:10.1002/iub.2211 · Cited by 61
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment
Raimondi, L., Luca, A. D., Morelli, E., Giavaresi, G., Tagliaferri, P., Tassone, P., & Amodio, N. (2016) · BioMed Research International · doi:10.1155/2016/6504593 · Cited by 56
The diagnostic and prognostic value of plasma microRNA‑125b‑5p in patients with multiple myeloma
Jiang, Y., Luan, Y., Chang, H., & Chen, G. (2018) · Oncology Letters · doi:10.3892/ol.2018.9128 · Cited by 36
MicroRNAs in multiple myeloma and related bone disease.
Rossi, M., Tagliaferri, P., & Tassone, P. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.12.13 · Cited by 35
miR-202 functions as a tumor suppressor in non-small cell lung cancer by targeting STAT3
Zhao, Z., Lv, B., Zhang, L., Zhao, N., & Lv, Y. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6841 · Cited by 35
RetractedZhu, B., Ju, S., Chu, H., Shen, X., Zhang, Y., Luo, X., & Cong, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.8157 · Cited by 35
Self-citationWang, J. J., Liu, Y., Ding, Z., Zhang, L., Han, C., Yan, C., Amador, E. H., Yuan, L., Wu, Y. G., Song, C., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.12.036 · Cited by 32
The microRNA-202 as a Diagnostic Biomarker and a Potential Tumor Suppressor
Ahmed, E. A., Rajendran, P., & Scherthan, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115870 · Cited by 32
Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2
Yen, C., Hsu, C., Hsiao, S. Y., & Hsiao, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186723 · Cited by 30
Ismail, N. H., Mussa, A., Al-Khreisat, M. J., Mohamed Yusoff, S., Husin, A., Al-Jamal, H. A. N., Johan, M. F., & Islam, M. A. (2023) · Non-Coding RNA · doi:10.3390/ncrna9060068 · Cited by 29
Kamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03741-x · Cited by 27
MicroRNA Transfer Between Bone Marrow Adipose and Multiple Myeloma Cells
Soley, L., Falank, C. R., & Reagan, M. R. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0360-5 · Cited by 25
NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma
Yen, C., & Hsiao, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113503 · Cited by 25
The role of circulating miRNAs in multiple myeloma
Zhang, J., Xiao, X., & Liu, J. (2015) · Science China Life Sciences · doi:10.1007/s11427-015-4969-2 · Cited by 24
Abdi, J., Rastgoo, N., Chen, Y., Chen, G. A., & Chang, H. (2019) · BMC Cancer · doi:10.1186/s12885-019-6151-x · Cited by 24
Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma
Allegra, A., Ettari, R., Innao, V., & Bitto, A. (2021) · Cells · doi:10.3390/cells10020448 · Cited by 22
Silk Biomaterials-Mediated miRNA Functionalized Orthopedic Devices
James, E. N., Doren, E. J. V., Li, C., & Kaplan, D. L. (2018) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0455 · Cited by 22
Therapeutic targets in myeloma bone disease
Marino, S., Petrusca, D. N., & Roodman, G. D. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14889 · Cited by 22
PDCD1 and PDCD1LG1 polymorphisms affect the susceptibility to multiple myeloma
Kasamatsu, T., Awata, M., Ishihara, R., Murakami, Y., Gotoh, N., Matsumoto, M., Sawamura, M., Yokohama, A., Handa, H., Tsukamoto, N., et al. (2019) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00585-4 · Cited by 21
Jin, J., Wang, T., Wang, Y., Chen, S., Li, Z., Li, X., Zhang, J., & Wang, J. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4171 · Cited by 19
Xiang, Y., Zhang, L.-Y., Xiang, P., & Zhang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698197 · Cited by 15
Ye, P., Song, X., Lan, J., Wang, X., & Wang, M. (2021) · Medicine · doi:10.1097/md.0000000000023447 · Cited by 15
Emerging roles of noncoding RNAs in multiple myeloma: A review
Yang, Q., Shen, X., Su, Z., & Ju, S. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27547 · Cited by 13
Self-citationQu, L., Li, J., Zhao, Z., Jiang, H., & Zhang, Q. (2017) · DNA and Cell Biology · doi:10.1089/dna.2016.3613 · Cited by 11
Zhi-yu, H., Liu, A., Yu, J., & Chen, X. (2022) · Contrast Media & Molecular Imaging · doi:10.1155/2022/1543604 · Cited by 9
Self-citationRetractedmiRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance
Pirzaman, A. T., Ebrahimi, P., Hasanpour, A., Shakeri, M., Babajani, B., Ganji, Z. P., Babaei, H., Rahmati, A., Hosseinzadeh, R., Doostmohamadian, S., et al. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231202391 · Cited by 9
Xu, F., Yao, F., & Ning, Y. (2023) · Gene · doi:10.1016/j.gene.2023.147366 · Cited by 9
Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment
Tang, W., Xu, J., & Xu, C. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216081 · Cited by 7
IDO2 rs10109853 polymorphism affects the susceptibility to multiple myeloma
Kasamatsu, T., Hashimoto, N., Sakaya, N., Awata, M., Ishihara, R., Murakami, Y., Masuda, Y., Gotoh, N., Nagai, K., Oda, T., et al. (2021) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00681-w · Cited by 7
Experimental treatment of multiple myeloma in the era of precision medicine
Martino, M. T. D., Arbitrio, M., Guzzi, P. H., Cannataro, M., Tagliaferri, P., & Tassone, P. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1142356 · Cited by 5
TAZ upregulates MIR‐224 to inhibit oxidative stress response in multiple myeloma
Abegunde, S. O., Grieve, S., & Reiman, T. (2023) · Cancer Reports · doi:10.1002/cnr2.1879 · Cited by 5
Zhang, Y., Shen, X., Wu, X., Cong, H., Ni, H., Ju, S., & Su, J. (2016) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2016.11.012 · Cited by 4
Self-citationmiR-125b expression affects tumor growth of multiple myeloma via targeting MKK7.
Jiang, Y., Luan, Y., He, D., & Chen, G. (2017) · PubMed · Cited by 2
Epigenetics of Multiple Myeloma Bone Disease
Pulugulla, S. H., & Adamik, J. (2019) · Current Molecular Biology Reports · doi:10.1007/s40610-019-0117-2 · Cited by 1
The Role of MicroRNAs in Mature B-Cell Neoplasias Drug Resistance
Bergantim, R., Jorge, J., da Silva, S. P., Alves, R., Gonçalves, A. C., Sarmento‐Ribeiro, A. B., Guimarães, J. E., & Vasconcelos, M. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00013-5 · Cited by 1
Metadata
- Authors
- Shen, X., Guo, Y., Yu, J., Qi, J., Shi, W., Wu, X., Ni, H., & Ju, S.
- Affiliations
- Affiliated Hospital of Nantong University (CN)
- Nantong University (CN)
- Soochow University (CN)
- Corresponding author
- Ju, Shaoqing
- Venue
- Clinical and Experimental Medicine
- Published
- 2015-05-14
- Volume
- 16
- Issue
- 3
- Pages
- 307-316
- ISSN
- 1591-8890 (ISSN-L)
- 1591-9528
- OpenAlex
- W222231233
- Cited by
- 37
- References
- 27
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 5 · 2022: 3 · 2021: 5 · 2020: 1 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 3 · 2015: 2
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Clinical and Experimental Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- The National Natural Science Foundation of China (81271920, 81301498)
- Jiangsu Provincial Program for Medical Innovation Teams and Leading Talents (LJ201133)
- Scientific Research Subject of Jiangsu Province Health Department (H201422)
- Six Major Human Resources Project of Jiangsu Province (20012-WS-119)
- Translational Medicine Project of Affiliated Hospital of Nantong University (TDF-zh201407)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- miR-202, mesenchymal stem cells, multiple myeloma, B-cell activating factor, BAFF, microRNA, cell adhesion, cell growth, Bcl-2, Bax, NF-κB signaling, bone marrow microenvironment, tumor cell survival
- MeSH terms
- Aged, B-Lymphocytes, Cell Adhesion, Female, Humans, Male, Middle Aged, Multiple Myeloma, Cyclins, Gene Expression Profiling, MicroRNAs, Cell Proliferation, bcl-2-Associated X Protein, B-Cell Activating Factor, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
